Steroid shield: new hope to prevent deadly immune Flare-Up in AIDS patients
NCT ID NCT07565623
First seen May 05, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study tests whether a short course of the steroid prednisolone can prevent a serious immune overreaction called IRIS in people with AIDS who have opportunistic infections and are starting HIV therapy. About 262 participants will be randomly assigned to receive either prednisolone or no extra treatment, and will be followed for 12 weeks. The main goal is to see if the steroid reduces the number of people who develop IRIS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV - HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.